JP2006507270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507270A5 JP2006507270A5 JP2004545186A JP2004545186A JP2006507270A5 JP 2006507270 A5 JP2006507270 A5 JP 2006507270A5 JP 2004545186 A JP2004545186 A JP 2004545186A JP 2004545186 A JP2004545186 A JP 2004545186A JP 2006507270 A5 JP2006507270 A5 JP 2006507270A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- beta
- gastrointestinal
- infection
- microbial infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 11
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 9
- 208000015181 infectious disease Diseases 0.000 claims 9
- 230000000813 microbial effect Effects 0.000 claims 8
- 208000010643 digestive system disease Diseases 0.000 claims 7
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000035874 Excoriation Diseases 0.000 claims 1
- 206010017964 Gastrointestinal infection Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000007501 Thymosin Human genes 0.000 claims 1
- 108010046075 Thymosin Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000022338 anthrax infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000019836 digestive system infectious disease Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35425002P | 2002-02-06 | 2002-02-06 | |
| US42103802P | 2002-10-25 | 2002-10-25 | |
| PCT/US2003/003455 WO2004035008A2 (en) | 2002-02-06 | 2003-02-06 | Treatment of infections and other disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006507270A JP2006507270A (ja) | 2006-03-02 |
| JP2006507270A5 true JP2006507270A5 (https=) | 2006-04-13 |
Family
ID=32109894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004545186A Pending JP2006507270A (ja) | 2002-02-06 | 2003-02-06 | 感染症および他の疾患の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060089310A1 (https=) |
| EP (2) | EP2266595A3 (https=) |
| JP (1) | JP2006507270A (https=) |
| AU (1) | AU2003296875B2 (https=) |
| CA (1) | CA2475053A1 (https=) |
| WO (1) | WO2004035008A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006076254A2 (en) * | 2005-01-11 | 2006-07-20 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing respiratory microbial infection of respiratory tissue |
| US9408891B2 (en) | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| AU2011218617B2 (en) * | 2004-05-12 | 2014-09-04 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat infections |
| KR101300929B1 (ko) * | 2004-05-12 | 2013-08-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 감염 치료를 위한 겔솔린의 용도 |
| KR100716119B1 (ko) * | 2005-10-24 | 2007-05-10 | (주)케어젠 | 모발 성장을 촉진하는 펩티드 및 이를 이용한 화장품 |
| KR101556790B1 (ko) | 2006-03-15 | 2015-10-01 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 염증성 질환의 진단 및 치료를 위한 겔솔린의 용도 |
| ES2651619T3 (es) | 2006-03-15 | 2018-01-29 | The Brigham And Women's Hospital, Inc. | Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas |
| US8399412B2 (en) | 2006-10-06 | 2013-03-19 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions |
| AU2008297426A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| WO2009046848A1 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| HUE032875T2 (en) | 2008-01-25 | 2017-11-28 | Massachusetts Gen Hospital | Diagnostic and therapeutic applications of gelsolin in renal failure |
| CA2718774A1 (en) * | 2008-03-17 | 2009-12-17 | Regenerx Biopharmaceuticals, Inc. | Improved beta thymosin fragments |
| US8580742B2 (en) * | 2010-03-05 | 2013-11-12 | N.V. Perricone Llc | Topical glutathione formulations for menopausal skin |
| US20110160144A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Formulations |
| US8609604B2 (en) | 2009-12-28 | 2013-12-17 | N.V. Perricone Llc | Methods of improving the appearance of aging skin |
| AU2011279539A1 (en) * | 2010-07-14 | 2013-03-07 | Adistem Ltd | Method of treatment of HIV or AIDS |
| CN103724422B (zh) * | 2014-01-13 | 2015-10-21 | 哈尔滨吉象隆生物技术有限公司 | 一种裂解胸腺素β4的方法 |
| US9710606B2 (en) | 2014-10-21 | 2017-07-18 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| US10073952B2 (en) | 2014-10-21 | 2018-09-11 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
| US9754080B2 (en) | 2014-10-21 | 2017-09-05 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions |
| US9760676B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| US10325685B2 (en) | 2014-10-21 | 2019-06-18 | uBiome, Inc. | Method and system for characterizing diet-related conditions |
| US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
| US10395777B2 (en) | 2014-10-21 | 2019-08-27 | uBiome, Inc. | Method and system for characterizing microorganism-associated sleep-related conditions |
| US10381112B2 (en) | 2014-10-21 | 2019-08-13 | uBiome, Inc. | Method and system for characterizing allergy-related conditions associated with microorganisms |
| US10777320B2 (en) | 2014-10-21 | 2020-09-15 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions |
| US11783914B2 (en) | 2014-10-21 | 2023-10-10 | Psomagen, Inc. | Method and system for panel characterizations |
| US10311973B2 (en) | 2014-10-21 | 2019-06-04 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
| US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
| US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
| US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
| US10357157B2 (en) | 2014-10-21 | 2019-07-23 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features |
| US10346592B2 (en) | 2014-10-21 | 2019-07-09 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| US10409955B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions |
| US10793907B2 (en) | 2014-10-21 | 2020-10-06 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
| AU2015335907A1 (en) | 2014-10-21 | 2017-04-13 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
| US10789334B2 (en) | 2014-10-21 | 2020-09-29 | Psomagen, Inc. | Method and system for microbial pharmacogenomics |
| US10366793B2 (en) | 2014-10-21 | 2019-07-30 | uBiome, Inc. | Method and system for characterizing microorganism-related conditions |
| US10246753B2 (en) | 2015-04-13 | 2019-04-02 | uBiome, Inc. | Method and system for characterizing mouth-associated conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4297276A (en) * | 1979-03-23 | 1981-10-27 | Hoffman-La Roche Inc. | Thymosin beta 3 and beta 4 |
| AU6204594A (en) * | 1993-02-22 | 1994-09-14 | Ulrich-Christoph Von Arnim | Use of heparins for the treatment of inflammatory or immunological diseases |
| US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
| GB9806632D0 (en) * | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
| EP1591128A1 (en) * | 1998-07-30 | 2005-11-02 | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health | Thymosin beta 4 promotes wound repair |
| CN1183310C (zh) * | 1999-04-14 | 2005-01-05 | 索斯科公司 | 月牙形铰链 |
| JP2005502672A (ja) * | 2001-08-29 | 2005-01-27 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | サイモシンβ4、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法 |
| CN108738377B (zh) | 2015-07-30 | 2020-11-10 | 株式会社半导体能源研究所 | 发光装置的制造方法、发光装置、模块及电子设备 |
-
2003
- 2003-02-06 AU AU2003296875A patent/AU2003296875B2/en not_active Ceased
- 2003-02-06 EP EP10185311A patent/EP2266595A3/en not_active Withdrawn
- 2003-02-06 CA CA002475053A patent/CA2475053A1/en not_active Abandoned
- 2003-02-06 WO PCT/US2003/003455 patent/WO2004035008A2/en not_active Ceased
- 2003-02-06 US US10/503,555 patent/US20060089310A1/en not_active Abandoned
- 2003-02-06 JP JP2004545186A patent/JP2006507270A/ja active Pending
- 2003-02-06 EP EP03808930A patent/EP1497322A4/en not_active Withdrawn
-
2008
- 2008-04-09 US US12/100,065 patent/US20110144020A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507270A5 (https=) | ||
| AU2018202201B2 (en) | Peptides and their use | |
| ES2565564T3 (es) | Una composición que comprende un antibiótico y un dispersante | |
| DK1739178T3 (da) | Levering af trekløverpeptider | |
| US20040106564A1 (en) | Use of slpi for treating chronic inflammatory intestinal diseases | |
| EP1718325B1 (en) | Treatment of bacterial infections | |
| AU2003296875A1 (en) | Treatment of infections and other disorders | |
| WO2003015809A9 (en) | Antimicrobial cationic peptides and formulations thereof | |
| CA2513567A1 (en) | Cop 1 for treatment of inflammatory bowel diseases | |
| WO2003018619A2 (en) | Antimicrobial and anti-inflammatory peptides | |
| JP2011068666A (ja) | 敗血症治療における経口用ラクトフェリン | |
| AU2013229486B2 (en) | Antimicrobial peptides | |
| JP2018531880A5 (https=) | ||
| JP2020138968A (ja) | インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物 | |
| JP2009500045A5 (https=) | ||
| JP2004534084A5 (https=) | ||
| JPS61186327A (ja) | 感染防禦剤 | |
| JP4554150B2 (ja) | 薬剤耐性菌による感染症治療剤 | |
| CN101247721B (zh) | 包括酪蛋白衍生肽的药物组合物及其使用方法 | |
| CN101342187A (zh) | 一种治疗痢疾的药物组合物 | |
| BRPI0710846A2 (pt) | composto de peptìdeo com atividade biológica, sua preparação e suas aplicações | |
| JP2009502810A5 (https=) | ||
| US20220133699A1 (en) | Antibacterial Compositions | |
| CN115776985A (zh) | 用于治疗真菌感染的组合物和方法 | |
| CN1299698C (zh) | 圆口纲动物唾液腺分泌物在制药中的应用 |